Held
HNGE · Hinge Health, Inc.
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 18 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Resolved Graded and closed 2026-06-18 at low conviction — the published kill line did not fire. Coverage continued after the close; the read below is dated 2026-09-20 and is not part of the scored record.
Current thesis
Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.
Kill line
A weekly close below $58 forfeits the June breakout above the $62.18 prior ATH and drops the tape back into its nine-month range; secondary breaks are the digital-MSK theme rolling to saturated or the ~2026-08-04 Q2 print landing under the raised $200–202M revenue floor.
Pick status
Played out resolved published kill line did not fire How this is scored →Latest analysis and events for HNGE —
As of 20 September 2026, the latest FrontierPicks analysis for Hinge Health, Inc. (HNGE): Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.
Kill line: A weekly close below $58 forfeits the June breakout above the $62.18 prior ATH and drops the tape back into its nine-month range; secondary breaks are the digital-MSK theme rolling to saturated or the ~2026-08-04 Q2 print landing under the raised $200–202M revenue floor.
Current Thesis
Hinge Health’s profitable digital musculoskeletal care story now has breakout confirmation; the continuation thesis requires third-quarter revenue of at least $223 million before a weekly close below $87.35. That revenue threshold is management’s 2026-08-04 guidance floor, while the price boundary retains the market’s 2026-08-28 reference close. Company outlook
The material change since the September 11 note is price confirmation: the adjusted September 18 close of $94.90 cleared the August 27 high of $92.85 that defined the earlier breakout objective. The refreshed case therefore turns on operating confirmation, rather than repeating an already reached price hurdle.
The inference remains that the narrative is maturing — the August 4 results received another valuation endorsement through Stifel’s September 8 target increase, and the September 18 close subsequently reached the supplied annual high. These observations establish continuing attention and price strength, but do not measure broader participation. A fresh company guidance increase accompanied by a weekly close above the September 18 reference of $94.90 would contradict that classification. Dated analyst actions
Bullish and bearish views on Hinge Health, Inc.
The model's bull view on Hinge Health, Inc. (HNGE), in brief: Growth includes cash generation. Hinge Health reported second-quarter revenue of $212.8 million, up 53% year over year, and free cash flow of $99.6 million on 2026-08-04. Those results substantiate the profitability narrative. Company results The prior price hurdle cleared. The… The bear view: Sponsor selling documents supply. The SEC Form 4 filed on 2026-08-27, accession 0001193125-26-371548, reported Bessemer-affiliated entities selling Class A shares on August 25 and August 26. These historical transactions do not establish September selling intensity or seller… Both cases follow in full.
Bull Case
- Growth includes cash generation. Hinge Health reported second-quarter revenue of $212.8 million, up 53% year over year, and free cash flow of $99.6 million on 2026-08-04. Those results substantiate the profitability narrative. Company results
- The prior price hurdle cleared. The adjusted weekly close of $94.90 on 2026-09-18 exceeded the market’s August 27 high of $92.85. This resolves the price-confirmation question left open in the September 11 note; subsequent operating delivery remains unreported.
Bear Case
- Sponsor selling documents supply. The SEC Form 4 filed on 2026-08-27, accession 0001193125-26-371548, reported Bessemer-affiliated entities selling Class A shares on August 25 and August 26. These historical transactions do not establish September selling intensity or seller motivation.
- Repurchase authority is discretionary. The 2026-08-04 release disclosed $300 million available for repurchases as of July 29 and stated that purchases were not obligatory. Authorization alone does not establish company demand behind September’s advance. Repurchase disclosure
Setup & Price Structure
The adjusted daily series records a September 18 close and annual high of $94.90, with a three-month price increase of 37.8%. The same snapshot reports a 14-period relative strength index of 63.3. These are price and momentum measurements; they do not identify the investors responsible for the advance.
Stifel raised its price target to $115 on September 8, according to Benzinga’s dated analyst table. That is Stifel’s valuation opinion, not a measured destination. The available evidence lacks a current moving-average level, dated short-interest update and systematic retail-participation series, so it cannot support a firm crowding conclusion. Analyst table
The $87.35 boundary remains the August 28 market reference used in the previous body. It is an explicit thesis threshold, not an independently established, repeatedly tested support shelf. Moderate conviction reflects the September 18 breakout alongside the absence of a newer operating result on the company’s investor-relations news page. Company news
Catalyst Calendar (next 30 days)
- 2026-09-30 — Third-quarter end. This is an accounting milestone, not a scheduled results announcement. As checked on September 20, the company’s event calendar did not identify an upcoming earnings release within the next 30 days. Company calendar
- ~2026-11-03 — Estimated third-quarter results. This remains the prior coverage’s unconfirmed planning date; the company calendar does not substantiate it. The eventual release tests management’s August 4 revenue outlook of $223–225 million. Company calendar
What Would Change Our Mind
Loss of the August reference would break the continuation structure: a weekly close below $87.35 invalidates the price thesis. Third-quarter revenue below $223 million would separately contradict the operating premise. The refreshed case plays out if reported third-quarter revenue meets that floor before the published weekly-close boundary is breached.
Correlation Notes
FrontierPicks’ Managed care & health services coverage classified the group as saturated on August 4 and retained that assessment through September 20; its listed peers are CNC, HUM and OSCR. That is an editorial assessment of the group, not a measured return correlation or a finding that Hinge Health’s own narrative has failed.
Hinge Health’s September 18 annual-high close provides a company-specific price observation despite that group assessment. No synchronized peer-return series accompanies the evidence, so neither sector independence nor a dependable diversification relationship can be established.
Notes
- Dual-class structure: Class B converts into Class A before insider open-market sales, so a Form 4 shows a conversion leg ahead of the sale line.
- Form 4 transaction code F is share withholding for RSU tax obligations, not a discretionary sale; code S is the open-market line.
- Rule 10b5-1 plans are active for executives and sponsor-affiliated funds, so Form 4s arrive on a schedule rather than in response to news.
- Guided operating margins are non-GAAP; GAAP figures are disclosed separately and ran materially lower before the Q2 2026 crossover.
- Float was 45.39M against 77.38M shares outstanding, with 13.73% of float short at the last reported update.
- Guided diluted share count of 85-87M sits above shares outstanding, so per-share comparisons drift as PSUs and RSUs settle.
Related · shared themes
OSCR
Oscar Health, Inc.
Oscar Health's higher earnings outlook and quantified 2027 pricing support a post-Investor-Day rerating. A weekly close above $32.76 before a weekly close below $29.83 would complete the price-confirmation test; the September 18, 2026 close of $32.13 leaves it unresolved.
CNC
Centene Corporation
Centene's margin-repair case requires sustained earnings guidance and a weekly close above $68.72 by its 2026-10-27 results. September's reaffirmation supports the earnings leg, but a weekly close below $65 or withdrawal or reduction of fiscal 2026 adjusted EPS guidance above $4.80 invalidates the case.
HUM
Humana Inc.
Humana's Medicare Advantage margin-recovery story faces a renewed price test: an adjusted daily close above $409.80 before a daily close below $383. The September 1, 2026 earnings reaffirmation supports stability, while October Star Ratings test the quality-bonus premise.
ASTH
Astrana Health Inc.
Astrana Health’s full-risk care story depends on meeting Q3 revenue and profit guidance while preserving its raised annual profit outlook. That operational result must arrive before a weekly close below $34 invalidates the recovery thesis.
See also · stocks to watch